Sono-Tek Corp (SOTK)
NASDAQInformation TechnologyIndustrial - MachinerySnapshot 2026-09-04
$5.02+0.80%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologyIndustrial - MachinerySnapshot 2026-09-04
QuarterlyIQ Insights · SOTK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow revenue modestly, driven by strong medical demand and higher-value production systems.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $5.13M in 2026-Q1 to $5.66M in 2027-Q1 (10% increase). Fiscal 2026 revenue was $20.9M, up 2% from $20.5M in FY 2025. Management consistently projects modest revenue growth driven by strong medical demand and higher-value production systems, and the financials show delivering progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Information Technology names rated strong grew net income 65% of the time over the next year (vs 52% for the rest of the cohort, n=6360).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company continues to project revenue growth during the first half of fiscal 2027, supported by strong medical demand and continued shipments of higher-value production systems.”
“We anticipate continued revenue growth in the first half of FY 2027 and profitability driven by the medical sector and sustained demand for high-ASP production systems.”
“We anticipate continued revenue growth and profitability in the first half of fiscal year 2027 compared to the first half of FY 2026, driven by expanding demand in the medical sector and continued ad…”
Focus on improving profitability and expanding gross margin through favorable product mix and operational discipline.
Stated as a priority in 3 of last 3 quarters. Gross margin expanded from 52% in 2026-Q1 to 57% in 2027-Q1, and operating income increased 86% in the same period. Fiscal 2026 operating income grew 81% year over year. Management's focus on margin expansion and profitability is supported by consistent financial improvement, indicating delivering progress.
“Fiscal 2027 is off to a strong start with double-digit revenue growth, meaningful margin expansion, and improved profitability.”
“We achieved strong profitability expansion with 51% gross margin for FY 2026 and operating income increased 81%.”
“Gross margin increased to 51% from 47.5%, driven by favorable product mix and increased U.S.-based system sales.”
Drive growth by expanding sales in the medical device market, including specialty stent coating and drug-eluting balloon platforms.
Stated as a priority in 3 of last 3 quarters. Medical sales surged 388% to $3.95M in 2027-Q1 from $0.81M in 2026-Q1, and increased 54% year over year in FY 2026. Management consistently emphasizes medical sector growth as a key driver, and the financials show strong delivery on this priority.
“Medical business was the primary growth driver with strong demand for specialty stent coating systems and Drug-Eluting Balloon platforms.”
“We are seeing strong momentum in the medical sector, with growing demand across applications such as stent coating and balloon catheter systems.”
“Demand in the medical sector is expanding and driving revenue growth in the first half of fiscal 2027.”
Maintain strong backlog while managing shipment timing and uncertainty in clean energy sectors affecting revenue visibility.
Stated as a priority in 3 of last 3 quarters. Backlog declined from $9.12M at fiscal 2026 year-end to $7.73M in 2027-Q1, reflecting shipment timing. Management highlights uncertainty in clean energy sectors and timing of large orders as factors limiting revenue visibility. This priority shows persistent focus with mixed delivery due to external timing risks.
“Full-year outlook reflects timing of several large production platform orders and uncertainty in clean energy sectors.”
“Visibility beyond first half remains limited due to uncertainty in clean energy sectors and timing of high ASP customer orders.”
“Continued uncertainty in certain clean energy sectors and timing of high ASP customer orders can create significant shifts in quarterly delivery timing.”
Focus on increasing cash generated from operations to strengthen financial position and support growth initiatives.
Over the trailing year it converted 1.35x of net income into operating cash flow. Historically, Information Technology names rated neutral grew net income 57% of the time over the next year (vs 52% for the rest of the cohort, n=4162).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
5 material management or governance events in the past 24 months, led by executive changes. Historically, Information Technology names rated stable grew net income 54% of the time over the next year (vs 60% for the rest of the cohort, n=2709).
Not investment advice. As of 2026-09-04.